Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second‐line <scp>Helicobacter pylori</scp> eradication in Japan<scp>,</scp> and the influence of metronidazole resistance

Murakami, Kazunari; Sato, Ryugo; Okimoto, Tadayoshi; Nasu, Masaru; Fujioka, Toshio; Kodama, Masaaki; Kagawa, Jiro

doi:10.1046/j.1365-2036.2003.01401.x

Cited by 90 publications

(109 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While the implementation of an H. pylori eradication regimen in Japan was delayed compared to those in the United States and Europe, our data on present resistance rates clearly suggest that first-line eradication failure as well as resistance to CLR will continue to increase in Japan. The effectiveness of a second-line H. pylori eradication regimen consisting of PPI in combination with AMX and MNZ has been reported in Japan, with eradication success rates ranging from 80 to 90% (15,16). As confirmed by our study, the low rate of resistance to MNZ will most likely lead to the greater use of MNZ in eradication regimens in Japan.…”

Section: Discussionsupporting

confidence: 76%

Changing Antimicrobial Susceptibility Epidemiology of Helicobacter pylori Strains in Japan between 2002 and 2005

et al. 2007

View full text Add to dashboard Cite

Surveillance ofWith a resistance rate of 19.2% among males compared to 27.0% among females, a significant gender difference was observed (P < 0.0001). Our study shows that in Japan, there is an evolving trend towards increased resistance to clarithromycin with geographical and gender differences as well as between clinical disease conditions. No significant changes in resistance were observed for amoxicillin and metronidazole during the period. While the benefit of H. pylori antimicrobial susceptibility testing has been debated in Japan, current empirical regimens are not based on susceptibility data representative of the general population. The development of an effective H. pylori eradication regimen in Japan will require continued resistance surveillance as well as a better understanding of the epidemiology of resistance.

show abstract

Section: Discussionsupporting

confidence: 76%

Changing Antimicrobial Susceptibility Epidemiology of Helicobacter pylori Strains in Japan between 2002 and 2005

et al. 2007

View full text Add to dashboard Cite

show abstract

“…[1][2][3] The first-line regimen for the treatment of H. pylori infection in Japan is triple therapy with a proton pump inhibitor (PPI), amoxicillin, and clarithromycin, whereas the secondline regimen consists of a PPI, amoxicillin, and metronidazole. 4,5 However, 2-3% of patients with H. pylori strains that are resistant to both first-and second-line regimens require third-line eradication therapy. 6,7 In addition, we previously showed that eradication could be achieved in about 80% of patients with seven-day 1 sitafloxacin-based triple therapy as a third-line regimen.…”

Section: Introductionmentioning

confidence: 99%

Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen forHelicobacter pylorieradication: A pilot study

Mori

Suzuki

Matsuzaki

et al. 2015

United European Gastroenterology Journal

View full text Add to dashboard Cite

Background and aim: This prospective randomized study was designed to assess the efficacy of 10-day and 14-day rifabutinbased triple therapy as a third-or fourth-line rescue therapy. Methods: Patients who failed first-and second-line eradication therapy were enrolled. H. pylori was isolated from gastric biopsy specimens and the rpoB mutation status, a factor of resistance to rifamycins, and minimum inhibitory concentrations (MICs) of rifabutin and amoxicillin were determined. Enrolled patients were randomly assigned to receive 10-day or 14-day eradication therapy with esomeprazole (20 mg, 4 times a day (q.i.d.)), amoxicillin (500 mg, q.i.d.), and rifabutin (300 mg, once a day (q.d.s.)). Poor compliance was defined as intake of <80% of study drugs. Successful H. pylori eradication was confirmed using a [13C] urea breath test or a stool antigen test, 12 weeks after the end of therapy. Results: Twelve patients were assigned to the 10-day group, and 17, to the 14-day group. Intention-to-treat and per-protocol analyses of eradication rates were 83.3% and 81.8% for the 10-day group and 94.1% and 91.7% for the 14-day group, respectively. All patients with rpoB mutation-positive strains (n ¼ 3) showed successful eradication, irrespective of the regimen received. Therapy was stopped due to adverse events in 8.3% and 29.3% of patients in the 10-day and 14-day groups, respectively. Conclusion: Both the 10-day and 14-day therapies were effective as rescue regimens. In particular, the 14-day therapy resulted in successful eradication in over 90% of patients, but the 10-day treatment may be enough to obtain a successful eradication rate, considering the tolerability of therapy.

show abstract

“…When the results of PPI/AC therapy are unsuccessful, the proportion of CAM-resistant patients increases after the treatment. Murakami, Sato et al, (2001) and Tankovic, Lamarque et al, (2001) reported percentages of CAM-resistant patients were 66.2% and 70%, respectively. The other issue is that PPI/AC therapy is only approved for reimbursement by the national health insurance in Japan as a secondary eradication regimen.…”

Section: Discussionmentioning

confidence: 95%

“…However in Brazil, the proportion of AMPC-resistant bacteria was 29% (Mendonca, (Murakami, Sato et al, 2001, Adamek, Suerbaum et al, 1998. It has been reported that the mechanism of AMPC resistance is (Dore, Graham et al, 1999, Okamoto, Yoshiyama et al, 2002.…”

Section: Discussionmentioning

confidence: 99%

Resistance to Antimicrobialagents in Eradication of Helicobacter Pylori Infection

Kawai

Kawakami

Kudo

et al. 2003

ACRT

View full text Add to dashboard Cite

Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second‐line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance

Cited by 90 publications

References 29 publications

Changing Antimicrobial Susceptibility Epidemiology of Helicobacter pylori Strains in Japan between 2002 and 2005

Changing Antimicrobial Susceptibility Epidemiology of Helicobacter pylori Strains in Japan between 2002 and 2005

Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen forHelicobacter pylorieradication: A pilot study

Resistance to Antimicrobialagents in Eradication of Helicobacter Pylori Infection

Contact Info

Product

Resources

About